A Phase I Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral CUDC-427, an Antagonist of Inhibitors of Apoptosis (IAP) Proteins, When Administered Twice Daily in Subjects With Advanced and Refractory Solid Tumors or Lymphoma

Trial Profile

A Phase I Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral CUDC-427, an Antagonist of Inhibitors of Apoptosis (IAP) Proteins, When Administered Twice Daily in Subjects With Advanced and Refractory Solid Tumors or Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs CUDC 427 (Primary)
  • Indications Diffuse large B cell lymphoma; Lymphoma; MALT lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Curis; Genentech
  • Most Recent Events

    • 13 Apr 2016 Status changed from recruiting to completed, as per results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 13 Apr 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 24 Feb 2015 According to a Curis media release, enrolment in the dose escalation cohorts of 100mg, 200mg and 300mg was completed during the fourth quarter of 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top